Serial Optical Coherence Tomography Assessment of Plaque Phenotype Stabilization after Paclitaxel-Coated Balloon Treatment in De Novo Coronary Lesions Authors: Eun-Seok Shin, Dong Oh Kang, Tae-Hyun Kim, Ae-Young Her, Sunwon Kim Published: 2026 ABSTRACT AbstractPurposeThere is limited evidence regarding serial plaque changes after paclitaxel-coated balloon (PCB) treatment in de novo coronary target lesions assessed using optical coherence tomography (OCT).Materials and MethodsA prospective serial OCT was performed on de novo target lesions in 48 patients (50 lesions) who underwent PCB treatment. Follow-up OCT was conducted for all lesions after a median of 6 months. The primary analysis evaluated changes in minimum fibrous cap thickness and maximum lipid arc across the imaged lesion segment.ResultsIn 2550 matched cross-sections from the analyzed lesions, the minimum fibrous cap thickness increased from 40.0±15.1 µm to 46.6±15.7 µm (p=0.007), and the maximum lipid arc decreased from 297.8±68.1° to 252.6±76.3° (p<0.001). The prevalence of thin-cap fibroatheroma (TCFA) decreased from 24.8% to 17.4% (p<0.001), and macrophage presence declined from 87.0% to 83.1% (p=0.001). At the lesion level, mean lumen area increased from 4.2±2.7 mm2 to 6.6±3.1 mm2, and minimum lumen area increased from 1.8±0.9 mm2 to 4.9±2.1 mm2 (both p<0.001). At the plaque level, 24 of 37 TCFA plaques at baseline changed to non-TCFA morphology (64.9%), while four of 40 non-TCFA plaques progressed to TCFA (10%).ConclusionAt 6 months after PCB treatment, target-lesion plaques exhibited OCT-derived changes consistent with a shift toward a less vulnerable plaque phenotype. The clinical implications of these imaging findings require further investigation.Keywords: Balloon angioplasty, paclitaxel, de novo, optical coherence tomography, percutaneous coronary intervention INTRODUCTION Drug-coated balloon (DCB) treatment is based on the mechanism of balloon angioplasty and aims to prevent restenosis through localized drug delivery following flow improvement via lesion preparation. Clinical evidence supporting the safety and efficacy of DCBs for the treatment of de novo coronary artery disease (CAD) is rapidly growing. Among these, the strongest evidence supports the use of paclitaxel-coated balloons (PCBs), which are increasingly being adopted in clinical practice as a viable therapeutic alternative. Paclitaxel is rapidly transferred to the vessel wall even with a short contact time between the DCB and the lesion, and, notably, it accumulates over time by penetrating through the media to reach the adventitia.1,2 The pharmacokinetic properties of paclitaxel explain its ability to inhibit intimal hyperplasia and chronic vascular recoil, which are key mechanisms of restenosis. In an animal study, PCB treatment reduced lesion inflammation, as demonstrated by near-infrared fluorescence-optical coherence tomography (OCT), and inhibited lesion progression on intravascular ultrasound, compared to both standard and sham balloon angioplasty.3 However, data on the safety profile of PCBs in human coronary plaque remain limited. Therefore, further studies are warranted to investigate the vascular effects of PCBs in de novo target lesions. This study aimed to evaluate the impact of PCBs on coronary plaque phenotype stabilization over time in de novo target lesions using OCT. MATERIALS AND METHODS Study design and population In this study, 48 patients with 50 target lesions who successfully underwent DCB-only percutaneous coronary intervention (PCI) for chronic coronary syndrome or stabilized acute coronary syndrome were prospectively enrolled between June 18, 2022, and July 21, 2023, at a single hospital (Ulsan University Hospital). Eligible patients were required to have at least one de novo coronary artery lesion, defined by a visually estimated reference vessel diameter between 2.5 mm and 3.5 mm. Key exclusion criteria included left main or three-vessel CAD, ST-segment elevation myocardial infarction, a history of coronary artery bypass surgery, or severe renal dysfunction. DCB treatment was performed in accordance with international and Asia-Pacific consensus recommendations, using a conventional balloon with a recommended balloon-to-vessel ratio of 0.8 to 1.0 in all lesions.4,5 A total of 48 patients completed serial OCT follow-up at 6 months. The change in OCT-derived efficacy measure from baseline to 6-month follow-up served as the primary endpoint. Two types of PCB catheter were used: SeQuent Please NEO (iopromide-based PCB: B. Braun, Melsungen, Germany) and Genoss PCB (wax-free shellac and vitamin E-based PCB: GENOSS Co., Ltd., Suwon, Korea). Following the procedure, all patients received daily aspirin (100 mg) and clopidogrel (75 mg). All patients attended clinical follow-up visits with their physician at the hospital where the procedure was performed. All patients were prescribed statin therapy at discharge after DCB-only PCI. Written informed consent was obtained from all participants. The study was approved by the Institutional Review Board of Ulsan University Hospital (IRB No. 2021-07-036). Acquisition and analysis of OCT Following baseline OCT imaging of the target lesions (Abbott OPTIS Mobile console with Dragonfly OPTIS catheter), all target lesions were treated with DCB. At 6 months, patients underwent a second OCT examination within the same lesion. OCT recordings were analyzed by one experienced investigator (Yoonha Noh) at the Ulsan University OCT core laboratory, who was blinded to the time-point of assessment and patient clinical characteristics. Analyses were performed offline using the OCT Offline Review Workstation at 1.0-mm intervals for the whole lesion and at 200-µm intervals within the matched lesion of interest. For serial matching, the analyzed “lesion of interest” was defined as a fixed-length OCT segment within the treated target lesion. Baseline and follow-up pullbacks were co-registered using anatomical landmarks (e.g., side branches and calcific deposits), and the segment was anchored by centering on the baseline minimum lumen area to standardize alignment and reduce subjective frame selection. The analysis was performed across all matched cross-sections within this predefined segment rather than a single minimum lumen area frame. For each image where lipid plaque was present, the analyst, blinded to the sequence of imaging studies (baseline vs follow-up) and treatment status, measured minimum fibrous cap thickness (determined as the thinnest point selected for measurement), as well as lipid arc, calcium arc, presence of macrophages, cholesterol crystals, and multi-layered plaque.6 Plaque classification by OCT was performed according to the international consensus statement.7 Fibroatheroma was defined as a plaque with evidence of a lipid pool >90° and no lateral delineation. Thin-cap fibroatheromas (TCFA) were defined by a minimum fibrous cap thickness <65 µm, whereas thick-cap fibroatheromas (ThCFA) were fibroatheromas with minimum FCT ≥65 µm. Fibrocalcific plaque was defined by evidence of calcification >90°. Fibrous plaque was defined by a homogeneous OCT signal with high backscatter and was any plaque not meeting either fibroatheroma or fibrocalcific plaque definitions. In this study, “plaque phenotype stabilization” refers to OCT-derived features consistent with a less vulnerable plaque phenotype (e.g., increased fibrous cap thickness, reduced lipid arc, lower prevalence of OCT-defined TCFA, and reduced macrophage signal). These imaging features do not imply a single biological mechanism, and findings potentially related to balloon-injury healing (e.g., layered plaque appearance) are interpreted separately. All measurements made by an analyst were subsequently reviewed by the core laboratory and a medical reviewer. Intraobserver reliability for the measurement of fibrous cap thickness (k=0.95) and lipid arc (k=0.98) was high. Study endpoints The primary endpoints were changes in minimum fibrous cap thickness and maximum lipid arc across the imaged lesion segment. Secondary endpoints included changes in mean fibrous cap thickness, mean lipid arc, presence of macrophages, presence of cholesterol crystals, and plaque type as assessed by OCT. Statistical analysis Continuous variables are presented as mean±SD, and categorical variables as counts and percentages. Lesion-level (per-lesion) serial comparisons between baseline and follow-up were performed using the paired Student’s t-test for continuous variables and the chi-square test for categorical variables. Since OCT provides multiple repeated cross-sections per lesion, serial changes were analyzed using linear mixed-effects models to account for clustering. Cross-sections were treated as repeated observations nested within lesions, with random intercepts specified at the lesion level (and at the patient level when a patient contributed more than one lesion). Time point (baseline vs. follow-up) was included as a fixed effect. This approach accounts for intra-lesion correlation and yields valid standard errors and p values for serial changes. Stratified analyses of serial OCT changes were conducted, and p values for interaction were obtained by including a time-by-stratum interaction term in the mixed-effects model (mixed-effects analysis of variance). Differences between strata were derived from linear mixed models. All statistical analyses were performed using R version 4.4.2 (R Foundation for Statistical Computing, Vienna, Austria), with a two-sided significance level of 0.05. RESULTS Baseline patient characteristics Table 1 summarizes the baseline characteristics of the study population. The mean age was 60 years, and the majority of patients were male. Half of the patients presented with stable angina, and two patients had non-ST segment elevation myocardial infarction. Two different types of DCB catheters were used: SeQuent Please NEO in 32 lesions and Genoss PCB in 18 lesions. All patients (n=48) had evaluable OCT imaging at both baseline and follow-up. The median follow-up duration was 185.0 days (interquartile range: 182.0 to 220.5 days). On quantitative coronary angiography, mean lesion length was 17.0±8.2 mm, reference vessel diameter was 2.9±0.4 mm, minimum lumen diameter was 1.2±0.3 mm, and diameter stenosis was 60.2±9.1%. The mean length of the lesion of interest, as assessed across all OCT cross-sections, was 10.4±0.0 mm. During the study period, 68.7% of patients were receiving high-intensity statin therapy (atorvastatin 40 mg±ezetimibe 10 mg or rosuvastatin 20 mg±ezetimibe 10 mg), and 31.3% were receiving moderate-intensity statin therapy (atorvastatin 20 mg±ezetimibe 10 mg). Table 1Baseline Patient Characteristics (n=48)ValueAge, yr60.8±7.5Sex, male39 (81.2)Body mass index (kg/m2)25.0±2.7Diabetes mellitus9 (18.8)Hypertension29 (60.4)Hyperlipidemia25 (52.1)Current smoking17 (35.4)Family history of CAD8 (16.7)Prior MI1 (2.1)Prior PCI1 (2.1)LVEF, %61.9±5.9Clinical diagnosisStable angina24 (50.0)Unstable angina22 (45.8)NSTEMI2 (4.2)Target coronary artery50 vesselsLeft anterior descending artery40 (80.0)Left circumflex artery6 (12.0)Right coronary artery4 (8.0)Quantitative coronary angiography50 lesionsReference vessel diameter, mm2.9±0.4Lesion length, mm17.0±8.2Minimal lumen diameter, mm1.2±0.3Diameter stenosis, %60.2±9.1DCB typeSeQuent Please NEO32 (64.0)Genoss PCB18 (36.0)Statin at dischargeAtorvastatin 20 mg+Ezetimibe 10 mg15 (31.3)Atorvastatin 40 mg+Ezetimibe 10 mg17 (35.4)Rosuvastatin 20 mg+Ezetimibe 10 mg16 (33.3)CAD, coronary artery disease; DCB, drug-coated balloon; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NSTEMI, non-ST segment elevation myocardial infarction; PCB, paclitaxel-coated balloon; PCI, percutaneous coronary intervention.Values are mean±SD or n (%). Baseline Patient Characteristics (n=48) CAD, coronary artery disease; DCB, drug-coated balloon; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NSTEMI, non-ST segment elevation myocardial infarction; PCB, paclitaxel-coated balloon; PCI, percutaneous coronary intervention. Values are mean±SD or n (%). Primary and secondary endpoints in target lesions Target lesions were imaged in all patients (left anterior descending artery: 80.0%, left circumflex artery: 12.0%, right coronary artery: 8.0%). Changes in OCT-defined atheroma characteristics throughout the target lesion are summarized in Table 2. The primary endpoint, the minimum fibrous cap thickness at any point in the lesion of interest, increased from 40.0±15.1 µm to 46.6±15.7 µm (p=0.007), representing a 14.2% increase. The maximum lipid arc decreased from 297.8±68.1° to 252.6±76.3° (p<0.001), corresponding to a 17.9% reduction (Fig. 1). The results of the secondary endpoints were as follows: 1) mean fibrous cap thickness increased from 106.3±55.9 µm to 123.2±64.8 µm (p<0.001); 2) mean lipid arc decreased from 206.2±87.6° to 167.7±81.0° (p<0.001); 3) macrophages decreased from 87.0% to 83.1% (p=0.001); 4) cholesterol crystals decreased from 16.4% to 13.0% (p=0.001); 5) the proportion of cross-sections exhibiting a multi-layered plaque pattern increased from 48.3% to 51.6% (p=0.019); and 6) plaque phenotype showed a trend toward a less vulnerable OCT-defined phenotype after DCB treatment. Specifically, there was a reduction in the proportion of TCFA and ThCFA plaques, as assessed by OCT. Table 3 summarizes plaque types, as assessed by OCT, in individual plaques (n=77 plaques within 50 target lesions) at baseline and follow-up. The most frequent changes in plaque morphology were observed in lesions classified as OCT-defined TCFAs at baseline; 24 of 37 TCFAs (64.9%) regressed to a non-TCFA phenotype. Among these, the majority (n=23) of TCFA transformed into ThCFA lesions, while one lesion regressed to a fibrous plaque. Conversely, only 4 out of 40 non-TCFA lesions (10.0%) progressed to TCFA at follow-up, all of which had been classified as ThCFA at baseline. Fibrocalcific plaques remained unchanged throughout the study period. Overall, most changes in plaque morphology shifted toward presumably more stable phenotypes (Fig. 2). Table 2Comparison of Serial OCT Findings between Baseline and Follow-Up after DCB Treatment in Target LesionsBaselineFollow-up p Lesion of interest within target lesion2550 cross sections2550 cross sectionsMean fibrous cap thickness, µm106.3±55.9123.2±64.8<0.001Minimum fibrous cap thickness, µm40.0±15.146.6±15.70.007Presence of thin fibrous cap (<65 µm)632 (24.8)444 (17.4)<0.001Mean lipid arc, °206.2±87.6167.7±81.0<0.001Maximum lipid arc, °297.8±68.1252.6±76.3<0.001Longitudinal lipid length, mm12.2±5.511.3±6.00.002Mean calcium arc, °12.9±31.512.9±30.50.936Maximum calcium arc, °47.7±55.448.8±54.60.571Longitudinal calcium length, mm0.7±2.00.7±1.90.980Presence of macrophages2218 (87.0)2120 (83.1)0.001Longitudinal macrophage length, mm1.2±2.81.0±1.40.467Cholesterol crystal419 (16.4)331 (13.0)0.001Multi–layered plaque1232 (48.3)1316 (51.6)0.019Whole target lesion50 lesions50 lesionsTotal plaque length (lesion length), mm16.0±6.216.1±6.20.717Mean lumen area, mm24.2±2.76.6±3.1<0.001Minimum lumen area, mm21.8±0.94.9±2.1<0.001Mean lumen eccentricity index0.76±0.130.77±0.10<0.001DCB, drug-coated balloon; OCT, optical coherence tomography.Values are mean±SD or n (%). Comparison of Serial OCT Findings between Baseline and Follow-Up after DCB Treatment in Target Lesions DCB, drug-coated balloon; OCT, optical coherence tomography. Values are mean±SD or n (%). Changes in minimum fibrous cap thickness (A) and maximum lipid arc (B) from baseline to follow-up. Table 3Evolution of Plaque Type from Baseline to Follow-Up in Target LesionsBaseline(n=77)Follow-up(n=77)TCFAThCFAFibrocalcific plaqueFibrous plaqueTCFA37 (48.0)13 (16.9)23 (29.9)01 (1.2)ThCFA21 (27.3)4 (5.2)13 (16.9)04 (5.2)Fibrocalcific plaque19 (24.7)0019 (24.7)0Fibrous plaque00000TCFA, thin-cap fibroatheroma; ThCFA, thick-cap fibroatheroma.Values are n (%). Evolution of Plaque Type from Baseline to Follow-Up in Target Lesions TCFA, thin-cap fibroatheroma; ThCFA, thick-cap fibroatheroma. Values are n (%). Serial changes in plaque type by optical coherence tomography. TCFA, thin-cap fibroatheroma; ThCFA, thick-cap fibroatheroma. Subgroup analyses of change in minimum fibrous cap thickness and maximum lipid arc In stratified analyses, significantly greater impact on the primary OCT endpoints was observed across all subgroups except for current smoking (Fig. 3). Specifically, the increase in minimum fibrous cap thickness was more pronounced in female patients (p for interaction=0.029), non-diabetic patients (p for interaction=0.014), patients with hypertension (p for interaction=0.028), non-current smokers (p for interaction<0.001), those with a target lesion in the left anterior descending artery (p for interaction=0.021), and those receiving high-intensity statin therapy (p for interaction=0.027), compared to their respective reference groups (Fig. 3A). A significantly greater reduction in the maximum lipid arc was consistently observed across all subgroups (Fig. 3B). The reduction was more pronounced in younger patients (p for interaction<0.001), patients without hyperlipidemia (p for interaction=0.001), those with acute coronary syndrome (p for interaction=0.009), those with a target lesion in the non-left anterior descending artery (p for interaction=0.031), and those with larger vessel disease (p for interaction<0.001), compared to their respective reference groups. Subgroup analyses of change in minimum fibrous cap thickness (A) and maximum lipid arc (B). CI, confidence interval; LAD, left anterior descending artery. DISCUSSION This prospective serial OCT study demonstrated that coronary plaques within de novo target lesions exhibited favorable morphological changes over time following PCB–based PCI, particularly in the context of contemporary statin therapy. In parallel, we observed a modest rise in multi-layered plaques at follow-up. Considering the mechanistic sequence of DCB therapy, namely balloon-induced plaque disruption followed by a reparative response, this pattern likely reflects plaque healing/layering rather than persistent vulnerability. Importantly, this observation occurred together with fibrous cap thickening, lipid arc reduction, lower macrophage presence, and the absence of adverse lumen remodeling (mean lumen area 4.2 → 6.6 mm2, minimum lumen area 1.8 → 4.9 mm2, both p<0.001). Although paclitaxel has known antiproliferative and potential anti-inflammatory properties, our study design does not allow definitive separation of injury-related healing from drug-specific biological effects on plaque composition. The concurrent reduction in lipid arc and macrophage signal, together with net regression of OCT-defined TCFA, is consistent with a shift toward a less vulnerable phenotype over time, although the relative contributions of local therapy and background medical treatment cannot be fully distinguished. Compared with baseline, PCB therapy significantly increased minimum fibrous cap thickness throughout the target lesion, which was the primary endpoint. Additionally, the maximum lipid arc was reduced on follow-up OCT. Similar trends were evident across secondary endpoints. Taken together, these findings suggest that PCB-only PCI was associated with favorable serial changes in the OCT-derived plaque phenotype, including fibrous cap thickening, reduced lipid arc, and lower prevalence of OCT-defined TCFA. These imaging findings are consistent with a shift toward a less vulnerable plaque phenotype; however, whether such changes translate into a lower risk of plaque rupture or fewer clinical events cannot be determined from the current study and should be considered hypothesis-generating. Although PCB has demonstrated improved efficacy in treating coronary restenosis and has become a primary treatment option for de novo CAD, data on its effects on plaque stability in coronary de novo target lesions remain limited. In a recent animal study, PCB reduced preclinical lesion inflammation and slowed lesion progression compared to plain balloon angioplasty, as demonstrated in vivo using serial intravascular near-infrared fluorescence-OCT imaging.3 In our previous studies, we showed that plaque modification and phenotype stabilization led to improved flow after PCB treatment, as assessed using intravascular imaging and physiology.8,9,10 PCB treatment for de novo coronary lesions demonstrated persistent anatomical and functional patency at 9-month follow-up. Plaque modification, vascular remodeling, and OCT-derived plaque phenotype stabilization were also observed during the follow-up. The DEBuT-LRP trial (ClinicalTrials.gov: NCT04765956)11 is currently ongoing and aims to evaluate the safety and feasibility of preventive treatment with a PCB for non-culprit, non-obstructive lipid-rich plaques by assessing changes in the maximum lipid core burden within a 4-mm segment after 9 months. The findings of this study may provide insights into whether localized treatment of lipid-rich plaques, in addition to guideline-directed medical therapy, enhances plaque phenotype stabilization. However, it does not evaluate the effect of PCB on plaque within the target lesion. In contrast, our study is unique in that it demonstrates that PCB not only directly prevents restenosis in the target lesion but also promotes plaque phenotype stabilization. This study is significant in that it goes beyond the conventional use of OCT for guiding lesion preparation or confirming the success of DCB treatment. Instead, it focuses on analyzing serial changes in plaque characteristics within target lesions following DCB treatment. All DCBs used in this study were coated with paclitaxel, enabling the assessment of its effects on target plaques. The findings demonstrated OCT-derived plaque phenotype changes; however, the independent contribution of paclitaxel cannot be established in the absence of a comparator arm and histopathologic correlation, and therefore remains hypothesis-generating. These findings should also be interpreted in the context of recent evidence on preventive PCI strategies, including the PREVENT trial, which demonstrated that PCI for non-flow-limiting vulnerable coronary plaques reduced major adverse cardiac events compared to optimal medical therapy alone.12 While the study found that preventive stenting did not increase the risk of serious adverse events over a 2-year follow-up period, long-term outcomes remain to be determined. Although these results are encouraging, stent-based therapies still face inherent limitations. New-generation drug-eluting stents (DESs) have significantly improved safety and efficacy compared to bare-metal stents and first-generation DESs; however, they continue to pose risks of both short- and long-term stent-related adverse events due to their permanent metallic structure.13,14,15 Moreover, stent implantation may impair vasomotor function in stented segments16 and accelerate neoatherosclerosis compared to native coronary lesions.17 Given these limitations, DCBs may offer a safe and effective alternative by delivering localized pharmacological treatment to vulnerable plaques without the need for a permanent implant. Statin therapy is a well-established pharmacological strategy known to delay plaque progression in both PCI-treated and non-culprit lesions. In a previous study, high-intensity statin therapy in non-culprit lesions of patients with myocardial infarction was associated with an increase in minimum fibrous cap thickness, a reduction in macrophage accumulation, and more frequent regression of TCFAs.18 Additionally, a recent study demonstrated that the proprotein convertase subtilisin/kexin type-9 inhibitor evolocumab induced favorable changes in coronary atherosclerosis, consistent with plaque phenotype stabilization and regression, as assessed by OCT in patients with non–ST-segment elevation myocardial infarction.19 Furthermore, statins may exert a more rapid and pronounced effect on vulnerable plaques. In a prior study, we reported that statin therapy led to a greater reduction in necrotic core within vulnerable plaques compared to stable plaques, as assessed by intravascular ultrasound-virtual histology.20 Since DCB treatment inherently causes iatrogenic plaque disruption, the effect of statins may be particularly beneficial in the acute period immediately following DCB treatment. As shown in Fig. 3B of this study, lipid reduction was more pronounced in lesions from patients with acute coronary syndrome, which are typically characterized by more vulnerable plaques, compared to those with chronic stable angina. Beyond its localized pharmacological effects, DCB treatment has the unique advantage of avoiding permanent metallic implants, thereby preserving the natural vessel architecture and its physiological functions. This characteristic enables a synergistic interaction with systemic secondary prevention strategies. In contrast to DES, which may impair vasomotor response or provoke neoatherosclerosis, DCB-treated segments remain receptive to the full benefits of medical therapy such as statins or PCSK9 inhibitors. Therefore, an implant-free local therapy strategy combined with optimized systemic prevention may represent a promising approach for plaque phenotype modulation; however, its impact on long-term clinical outcomes requires confirmation in larger randomized trials with clinical endpoints. Mechanistically, DCB angioplasty can induce iatrogenic plaque disruption/dissection that triggers a vascular healing response, while localized drug delivery suppresses subsequent restenosis; accordingly, although DCB may be applicable for target lesions, its preventive use in non-target lesions remains investigational and requires validation in randomized trials with clinical endpoints. This study had some limitations. First, this study was not designed to determine the independent plaque-stabilizing effect of PCBs. Without histopathologic correlation or a comparator group (e.g., plain balloon angioplasty under otherwise identical procedural and medical therapy conditions), we cannot determine the extent to which OCT-observed cap thickening reflects balloon injury healing versus any paclitaxel-specific plaque-stabilizing effect; thus, paclitaxel-driven biological stabilization should be regarded as hypothesis-generating. Second, our endpoints were OCT-derived surrogate measures of plaque phenotype and vulnerability. Although these metrics are useful for mechanistic assessment and have been widely used in intravascular imaging studies, they do not constitute clinical outcome data; thus, no inference can be made regarding long-term prognostic benefit or event reduction based on the present study. Third, two PCB platforms were used, and the study was not designed or powered to evaluate device-specific effects or device-by-statin interactions. In conclusion, PCB-only PCI was associated with favorable serial changes in OCT-derived plaque characteristics in de novo coronary target lesions, consistent with a shift toward a less vulnerable plaque phenotype. Further studies are needed to determine whether these imaging findings translate into improved clinical outcomes. ACKNOWLEDGEMENTS The authors thank Yoonha Noh for her assistance with OCT data analysis and Bitna Kim for her support with statistical analysis. Footnotes The authors have no potential conflicts of interest to disclose. AUTHOR CONTRIBUTIONS: Conceptualization: Eun-Seok Shin.Data curation: all authors.Formal analysis: Eun-Seok Shin.Funding acquisition: Eun-Seok Shin.Investigation: all authors.Methodology: Eun-Seok Shin.Project administration: Eun-Seok Shin.Resources: Eun-Seok Shin.Software: Eun-Seok Shin.Supervision: Eun-Seok Shin.Validation: Eun-Seok Shin.Visualization: Eun-Seok Shin.Writing—original draft: Eun-Seok Shin.Writing—review & editing: Eun-Seok Shin.Approval of final manuscript: all authors. Conceptualization: Eun-Seok Shin. Conceptualization: Eun-Seok Shin. Data curation: all authors. Data curation: all authors. Formal analysis: Eun-Seok Shin. Formal analysis: Eun-Seok Shin. Funding acquisition: Eun-Seok Shin. Funding acquisition: Eun-Seok Shin. Investigation: all authors. Investigation: all authors. Methodology: Eun-Seok Shin. Methodology: Eun-Seok Shin. Project administration: Eun-Seok Shin. Project administration: Eun-Seok Shin. Resources: Eun-Seok Shin. Resources: Eun-Seok Shin. Software: Eun-Seok Shin. Software: Eun-Seok Shin. Supervision: Eun-Seok Shin. Supervision: Eun-Seok Shin. Validation: Eun-Seok Shin. Validation: Eun-Seok Shin. Visualization: Eun-Seok Shin. Visualization: Eun-Seok Shin. Writing—original draft: Eun-Seok Shin. Writing—original draft: Eun-Seok Shin. Writing—review & editing: Eun-Seok Shin. Writing—review & editing: Eun-Seok Shin. Approval of final manuscript: all authors. Approval of final manuscript: all authors. DATA AVAILABILITY STATEMENT The data underlying this article will be shared upon reasonable request to the corresponding author. References Associated Data Data Availability Statement The data underlying this article will be shared upon reasonable request to the corresponding author.